Immunizing against Anogenital Cancer: HPV Vaccines

Pogoda, Cloe S.; Roden, Richard B.S.; Garcea, Robert L.

doi:10.1371/journal.ppat.1005587

Cited by 31 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, 5-year overall survival rates with this treatment are about only 50% [6]. Although the availability of two HPV vaccines, Cervarix ® or Gardasil ® , offer prophylactic protection against a minor fraction of HPV types-associated cervical lesions, they are not effective for existing post-HPV infection lesions [7,8]. What's more, the cost of vaccination programs makes them inappropriate for developing countries.…”

Section: Introductionmentioning

confidence: 99%

Involvement of p53-dependent apoptosis signal in antitumor effect of Colchicine on human papilloma virus (HPV)-positive human cervical cancer cells

et al. 2020

View full text Add to dashboard Cite

Colchicine, a plant-derived alkaloid with relatively low toxicity on normal human epidermal keratinocytes (HEKn), has selective inhibitory effect on the growth of CaSki (HPV16-positive) and HeLa (HPV18-positive) human cervical cancer cell lines via the induction of apoptosis. Colchicine (2.5, 5.0 and 10.0 ng/ml) significantly reduced the expression of human papilloma virus (HPV) 16 E6/E7 mRNA and protein in CaSki and HeLa cells. Moreover, reduced expression of E6 and E7 induced by Colchicine resulted in the up-regulation of tumor suppressor proteins, p53 and Rb, as well as down-regulation of phospho Rb (pRb) protein. In addition, Bax, cytosolic cytochrome c and cleaved caspase-3 protein were increased while Bcl-2 protein was decreased significantly by 48 h of Colchicine treatment. These results implied that Colchicine could be explored as a potent candidate agent for the treatment and prevention of HPV-associated cervical cancer without deleterious effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Involvement of p53-dependent apoptosis signal in antitumor effect of Colchicine on human papilloma virus (HPV)-positive human cervical cancer cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, detection of HPV integration into the human genome by NGS as a means of screening for cervical cancer is becoming a new strategy based on HPV screening. Many studies have confirmed that HPV integration and CIN progression are also closely related . HPV integration often occurs in low‐grade cervical intraepithelial lesions in the early stage and then progressing to high‐grade intraepithelial lesions .…”

Section: New Concepts and Technologies For Early Prevention And Treatmentioning

confidence: 95%

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

2018

Cancer Medicine

268

140

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer in women worldwide, with concepts and knowledge about its prevention and treatment evolving rapidly. Human papillomavirus (HPV) has been identified as a major factor that leads to cervical cancer, although HPV infection alone cannot cause the disease. In fact, HPV‐driven cancer is a small probability event because most infections are transient and could be cleared spontaneously by host immune system. With persistent HPV infection, decades are required for progression to cervical cancer. Therefore, this long time window provides golden opportunity for clinical intervention, and the fundament here is to elucidate the carcinogenic pattern and applicable targets during HPV‐host interaction. In this review, we discuss the key factors that contribute to the persistence of HPV and cervical carcinogenesis, emerging new concepts and technologies for cancer interventions, and more urgently, how these concepts and technologies might lead to clinical precision medicine which could provide prediction, prevention, and early treatment for patients.

show abstract

“…The strongest argument for an etiological role of a virus in cancer development is the application of a prophylactic vaccine that prevents tumor formation. In the case of anogenital tumors, three HPV vaccines (Cervarix, Gardasil, and Gardasil 9), consisting of L1 (the major papillomavirus virion protein)-based virus-like particles (VLPs) are currently licensed ( Pogoda et al, 2016 ). They are targeted against two, four, or nine mucosal HPV types (HPV6, 11, 16, 18, 31, 33, 45, 52, and 58), respectively, and – regardless of being very effective – they present limitations, making the development of broad protective second-generation HPV vaccines necessary.…”

Section: Current Work and Perspectives On Vaccination Against Cutaneomentioning

confidence: 99%

Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

2018

View full text Add to dashboard Cite

There is still controversy in the scientific field about whether certain types of cutaneous human papillomaviruses (HPVs) are causally involved in the development of non-melanoma skin cancer (NMSC). Deciphering the etiological role of cutaneous HPVs requires – besides tissue culture systems – appropriate preclinical models to match the obtained results with clinical data from affected patients. Clear scientific evidence about the etiology and underlying mechanisms involved in NMSC development is fundamental to provide reasonable arguments for public health institutions to classify at least certain cutaneous HPVs as group 1 carcinogens. This in turn would have implications on fundraising institutions and health care decision makers to force – similarly as for anogenital cancer – the implementation of a broad vaccination program against “high-risk” cutaneous HPVs to prevent NMSC as the most frequent cancer worldwide. Precise knowledge of the multi-step progression from normal cells to cancer is a prerequisite to understand the functional and clinical impact of cofactors that affect the individual outcome and the personalized treatment of a disease. This overview summarizes not only recent arguments that favor the acceptance of a viral etiology in NMSC development but also reflects aspects of causality in medicine, the use of empirically meaningful model systems and strategies for prevention.

show abstract

Immunizing against Anogenital Cancer: HPV Vaccines

Cited by 31 publications

References 20 publications

Involvement of p53-dependent apoptosis signal in antitumor effect of Colchicine on human papilloma virus (HPV)-positive human cervical cancer cells

Involvement of p53-dependent apoptosis signal in antitumor effect of Colchicine on human papilloma virus (HPV)-positive human cervical cancer cells

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?

Contact Info

Product

Resources

About